{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.7","upperLimit":"17.9","value":"10.8"},{"comment":"NA - Not reachable","groupId":"OG001","lowerLimit":"7.9","upperLimit":"NA","value":"24.3"},{"groupId":"OG002","lowerLimit":"4.6","upperLimit":"17.6","value":"10.1"},{"groupId":"OG003","lowerLimit":"6.8","upperLimit":"22.4","value":"11.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the time from the first dose until death due to any cause. No hypothesis testing completed for cohort A,B,C and D","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.","id":"OG000","title":"Cohort A"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG001","title":"Cohort B"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG002","title":"Cohort C"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG003","title":"Cohort D"}],"paramType":"MEDIAN","populationDescription":"All Treated population - All subjects who receive at least one dose of study medication are comprised the All Treated subjects (ATS) population","reportingStatus":"POSTED","timeFrame":"From the first dose to death","title":"Overall Survival (OS) for Each Cohort","type":"SECONDARY","unitOfMeasure":"Month"}